Markets

Validea's Top Five Healthcare Stocks Based On Motley Fool - 6/16/2019

The following are the top rated Healthcare stocks according to Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.

ATRION CORPORATION (ATRI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Motley Fool is 83% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company's medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology. Its cardiovascular product, MPS2 Myocardial Protection System (MPS2), is the system used in open-heart surgery that delivers fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The Company manufactures specialized medical devices that disinfect contact lenses. Its other medical and non-medical product lines consist of instrumentation and associated disposables.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

PROFIT MARGIN: PASS
RELATIVE STRENGTH: PASS
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL
INSIDER HOLDINGS: PASS
CASH FLOW FROM OPERATIONS: PASS
PROFIT MARGIN CONSISTENCY: PASS
R&D AS A PERCENTAGE OF SALES: NEUTRAL
CASH AND CASH EQUIVALENTS: PASS
INVENTORY TO SALES: PASS
ACCOUNTS RECEIVABLE TO SALES: PASS
LONG TERM DEBT/EQUITY RATIO: PASS
"THE FOOL RATIO" (P/E TO GROWTH): FAIL
AVERAGE SHARES OUTSTANDING: PASS
SALES: PASS
DAILY DOLLAR VOLUME: PASS
PRICE: PASS
INCOME TAX PERCENTAGE: FAIL

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

REPLIGEN CORPORATION (RGEN) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 79% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

PROFIT MARGIN: PASS PROFIT MARGIN: PASS
RELATIVE STRENGTH: PASS RELATIVE STRENGTH: PASS
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS
INSIDER HOLDINGS: PASS INSIDER HOLDINGS: PASS
CASH FLOW FROM OPERATIONS: PASS CASH FLOW FROM OPERATIONS: PASS
PROFIT MARGIN CONSISTENCY: PASS PROFIT MARGIN CONSISTENCY: FAIL
R&D AS A PERCENTAGE OF SALES: NEUTRAL R&D AS A PERCENTAGE OF SALES: PASS
CASH AND CASH EQUIVALENTS: PASS CASH AND CASH EQUIVALENTS: PASS
INVENTORY TO SALES: PASS INVENTORY TO SALES: PASS
ACCOUNTS RECEIVABLE TO SALES: PASS ACCOUNTS RECEIVABLE TO SALES: PASS
LONG TERM DEBT/EQUITY RATIO: PASS LONG TERM DEBT/EQUITY RATIO: PASS
"THE FOOL RATIO" (P/E TO GROWTH): FAIL "THE FOOL RATIO" (P/E TO GROWTH): FAIL
AVERAGE SHARES OUTSTANDING: PASS AVERAGE SHARES OUTSTANDING: PASS
SALES: PASS SALES: PASS
DAILY DOLLAR VOLUME: PASS DAILY DOLLAR VOLUME: FAIL
PRICE: PASS PRICE: PASS
INCOME TAX PERCENTAGE: FAIL INCOME TAX PERCENTAGE: FAIL

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

BIOLIFE SOLUTIONS INC (BLFS) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 76% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

PROFIT MARGIN: PASS PROFIT MARGIN: PASS PROFIT MARGIN: PASS
RELATIVE STRENGTH: PASS RELATIVE STRENGTH: PASS RELATIVE STRENGTH: PASS
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL
INSIDER HOLDINGS: PASS INSIDER HOLDINGS: PASS INSIDER HOLDINGS: PASS
CASH FLOW FROM OPERATIONS: PASS CASH FLOW FROM OPERATIONS: PASS CASH FLOW FROM OPERATIONS: PASS
PROFIT MARGIN CONSISTENCY: PASS PROFIT MARGIN CONSISTENCY: FAIL PROFIT MARGIN CONSISTENCY: PASS
R&D AS A PERCENTAGE OF SALES: NEUTRAL R&D AS A PERCENTAGE OF SALES: PASS R&D AS A PERCENTAGE OF SALES: FAIL
CASH AND CASH EQUIVALENTS: PASS CASH AND CASH EQUIVALENTS: PASS CASH AND CASH EQUIVALENTS: PASS
INVENTORY TO SALES: PASS INVENTORY TO SALES: PASS INVENTORY TO SALES: PASS
ACCOUNTS RECEIVABLE TO SALES: PASS ACCOUNTS RECEIVABLE TO SALES: PASS ACCOUNTS RECEIVABLE TO SALES: PASS
LONG TERM DEBT/EQUITY RATIO: PASS LONG TERM DEBT/EQUITY RATIO: PASS LONG TERM DEBT/EQUITY RATIO: PASS
"THE FOOL RATIO" (P/E TO GROWTH): FAIL "THE FOOL RATIO" (P/E TO GROWTH): FAIL "THE FOOL RATIO" (P/E TO GROWTH): FAIL
AVERAGE SHARES OUTSTANDING: PASS AVERAGE SHARES OUTSTANDING: PASS AVERAGE SHARES OUTSTANDING: PASS
SALES: PASS SALES: PASS SALES: PASS
DAILY DOLLAR VOLUME: PASS DAILY DOLLAR VOLUME: FAIL DAILY DOLLAR VOLUME: PASS
PRICE: PASS PRICE: PASS PRICE: PASS
INCOME TAX PERCENTAGE: FAIL INCOME TAX PERCENTAGE: FAIL INCOME TAX PERCENTAGE: FAIL

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

BIOSPECIFICS TECHNOLOGIES CORP. (BSTC) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 76% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren's contracture and Peyronie's disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

PROFIT MARGIN: PASS PROFIT MARGIN: PASS PROFIT MARGIN: PASS PROFIT MARGIN: PASS
RELATIVE STRENGTH: PASS RELATIVE STRENGTH: PASS RELATIVE STRENGTH: PASS RELATIVE STRENGTH: PASS
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL
INSIDER HOLDINGS: PASS INSIDER HOLDINGS: PASS INSIDER HOLDINGS: PASS INSIDER HOLDINGS: PASS
CASH FLOW FROM OPERATIONS: PASS CASH FLOW FROM OPERATIONS: PASS CASH FLOW FROM OPERATIONS: PASS CASH FLOW FROM OPERATIONS: PASS
PROFIT MARGIN CONSISTENCY: PASS PROFIT MARGIN CONSISTENCY: FAIL PROFIT MARGIN CONSISTENCY: PASS PROFIT MARGIN CONSISTENCY: PASS
R&D AS A PERCENTAGE OF SALES: NEUTRAL R&D AS A PERCENTAGE OF SALES: PASS R&D AS A PERCENTAGE OF SALES: FAIL R&D AS A PERCENTAGE OF SALES: FAIL
CASH AND CASH EQUIVALENTS: PASS CASH AND CASH EQUIVALENTS: PASS CASH AND CASH EQUIVALENTS: PASS CASH AND CASH EQUIVALENTS: PASS
INVENTORY TO SALES: PASS INVENTORY TO SALES: PASS INVENTORY TO SALES: PASS ACCOUNTS RECEIVABLE TO SALES: PASS
ACCOUNTS RECEIVABLE TO SALES: PASS ACCOUNTS RECEIVABLE TO SALES: PASS ACCOUNTS RECEIVABLE TO SALES: PASS LONG TERM DEBT/EQUITY RATIO: PASS
LONG TERM DEBT/EQUITY RATIO: PASS LONG TERM DEBT/EQUITY RATIO: PASS LONG TERM DEBT/EQUITY RATIO: PASS "THE FOOL RATIO" (P/E TO GROWTH): PASS
"THE FOOL RATIO" (P/E TO GROWTH): FAIL "THE FOOL RATIO" (P/E TO GROWTH): FAIL "THE FOOL RATIO" (P/E TO GROWTH): FAIL AVERAGE SHARES OUTSTANDING: PASS
AVERAGE SHARES OUTSTANDING: PASS AVERAGE SHARES OUTSTANDING: PASS AVERAGE SHARES OUTSTANDING: PASS SALES: PASS
SALES: PASS SALES: PASS SALES: PASS DAILY DOLLAR VOLUME: PASS
DAILY DOLLAR VOLUME: PASS DAILY DOLLAR VOLUME: FAIL DAILY DOLLAR VOLUME: PASS PRICE: PASS
PRICE: PASS PRICE: PASS PRICE: PASS INCOME TAX PERCENTAGE: FAIL
INCOME TAX PERCENTAGE: FAIL INCOME TAX PERCENTAGE: FAIL INCOME TAX PERCENTAGE: FAIL

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

CHINA BIOLOGIC PRODUCTS HOLDINGS INC (CBPO) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Motley Fool is 76% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Company Description: China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company's products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).

The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.

PROFIT MARGIN: PASS PROFIT MARGIN: PASS PROFIT MARGIN: PASS PROFIT MARGIN: PASS PROFIT MARGIN: PASS
RELATIVE STRENGTH: PASS RELATIVE STRENGTH: PASS RELATIVE STRENGTH: PASS RELATIVE STRENGTH: PASS RELATIVE STRENGTH: FAIL
COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: FAIL COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: PASS
INSIDER HOLDINGS: PASS INSIDER HOLDINGS: PASS INSIDER HOLDINGS: PASS INSIDER HOLDINGS: PASS INSIDER HOLDINGS: PASS
CASH FLOW FROM OPERATIONS: PASS CASH FLOW FROM OPERATIONS: PASS CASH FLOW FROM OPERATIONS: PASS CASH FLOW FROM OPERATIONS: PASS CASH FLOW FROM OPERATIONS: PASS
PROFIT MARGIN CONSISTENCY: PASS PROFIT MARGIN CONSISTENCY: FAIL PROFIT MARGIN CONSISTENCY: PASS PROFIT MARGIN CONSISTENCY: PASS PROFIT MARGIN CONSISTENCY: FAIL
R&D AS A PERCENTAGE OF SALES: NEUTRAL R&D AS A PERCENTAGE OF SALES: PASS R&D AS A PERCENTAGE OF SALES: FAIL R&D AS A PERCENTAGE OF SALES: FAIL R&D AS A PERCENTAGE OF SALES: PASS
CASH AND CASH EQUIVALENTS: PASS CASH AND CASH EQUIVALENTS: PASS CASH AND CASH EQUIVALENTS: PASS CASH AND CASH EQUIVALENTS: PASS CASH AND CASH EQUIVALENTS: PASS
INVENTORY TO SALES: PASS INVENTORY TO SALES: PASS INVENTORY TO SALES: PASS ACCOUNTS RECEIVABLE TO SALES: PASS INVENTORY TO SALES: PASS
ACCOUNTS RECEIVABLE TO SALES: PASS ACCOUNTS RECEIVABLE TO SALES: PASS ACCOUNTS RECEIVABLE TO SALES: PASS LONG TERM DEBT/EQUITY RATIO: PASS ACCOUNTS RECEIVABLE TO SALES: PASS
LONG TERM DEBT/EQUITY RATIO: PASS LONG TERM DEBT/EQUITY RATIO: PASS LONG TERM DEBT/EQUITY RATIO: PASS "THE FOOL RATIO" (P/E TO GROWTH): PASS LONG TERM DEBT/EQUITY RATIO: PASS
"THE FOOL RATIO" (P/E TO GROWTH): FAIL "THE FOOL RATIO" (P/E TO GROWTH): FAIL "THE FOOL RATIO" (P/E TO GROWTH): FAIL AVERAGE SHARES OUTSTANDING: PASS "THE FOOL RATIO" (P/E TO GROWTH): FAIL
AVERAGE SHARES OUTSTANDING: PASS AVERAGE SHARES OUTSTANDING: PASS AVERAGE SHARES OUTSTANDING: PASS SALES: PASS AVERAGE SHARES OUTSTANDING: PASS
SALES: PASS SALES: PASS SALES: PASS DAILY DOLLAR VOLUME: PASS SALES: PASS
DAILY DOLLAR VOLUME: PASS DAILY DOLLAR VOLUME: FAIL DAILY DOLLAR VOLUME: PASS PRICE: PASS DAILY DOLLAR VOLUME: PASS
PRICE: PASS PRICE: PASS PRICE: PASS INCOME TAX PERCENTAGE: FAIL PRICE: PASS
INCOME TAX PERCENTAGE: FAIL INCOME TAX PERCENTAGE: FAIL INCOME TAX PERCENTAGE: FAIL INCOME TAX PERCENTAGE: FAIL

For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

Since its inception, Validea's strategy based on Motley Fool has returned 501.77% vs. 190.41% for the S&P 500. For more details on this strategy, click here

About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' "Fool" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.

About Validea: Validea is an investment research service that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

    Validea

    At Validea we believe the best way to outperform the market is to follow the investment factors and strategies that have done so over long periods of time. Since 2003, our team has been dedicated to bringing the fundamental strategies of great investors and academics to the professional and retail investment communities via the tools, portfolios and research found on Validea.

    Learn More